Cardiff Oncology (CRDF) news
Recent news
Cardiff Oncology, Inc.: H.C. Wainwright raises to buy from neutral
H.C. Wainwright & Co. has upgraded Cardiff Oncology, Inc. (NASDAQ: CRDF) to "Buy" from "Neutral," assigning a $9 price target for the stock. This decision follows the company’s recent settlement with Nerviano Medical Sciences, which amended their 2017 license agreement and resolved all outstanding…
AInvest Wire · Sep 15, 2026Cardiff Oncology scores major legal win, settles dispute with Nerviano Medical Sciences
Cardiff Oncology has reached a settlement in its legal dispute with Nerviano Medical Sciences S.r.l., resolving a long-standing conflict between the two entities. The agreement amends the existing licensing arrangement and brings closure to litigation that had previously been filed by Cardiff…
AInvest Wire · Sep 14, 2026Cardiff Oncology - No admission of liability or monetary payment in Cardiff-Nerviano settlement - SEC filing
Cardiff Oncology, Inc. has disclosed details regarding a settlement agreement with Nerviano Medical Sciences S.r.l. in a recent SEC filing. According to the filing, the resolution does not involve any admission of liability by the company nor does it require a monetary payment from Cardiff Oncology…
AInvest Wire · Sep 14, 2026Cardiff Oncology, - Co and NMS to jointly request dismissal of all claims with prejudice
AInvest Wire · Sep 14, 2026Cardiff Oncology, - Co and NMS agree to full mutual release of all claims in litigation
AInvest Wire · Sep 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.